36.59 
0.17(0.47%) Jun 18, 4:00PM EDT|After Hours
:
36.59 0.00 (0.00%) Jun 18, 5:27PM EDT
| Prev Close: | 36.42 |
|---|
| Open: | 36.46 |
|---|
| Bid: | 28.45 x 400 |
|---|
| Ask: | 40.00 x 200 |
|---|
| 1y Target Est: | 31.35 |
|---|
| Beta: | 0.66 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 36.15 - 36.60 |
|---|
| 52wk Range: | 28.62 - 37.78 |
|---|
| Volume: | 370,938 |
|---|
| Avg Vol (3m): | 1,219,910 |
|---|
| Market Cap: | 6.06B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.44 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Is This Hurting Healthcare Company Priced for a Recovery?at Motley Fool(Fri, Jun 14)
- ICU Medical draws interest from CareFusion as bids loom -sourcesat Reuters(Fri, Jun 7)
- Hospira: A Case Study For Strategic Valuationat Seeking Alpha(Thu, Jun 6)
- Hospira Data on European Biosimilar Epoetin, Retacrit, Affirm Treatment Response, Tolerability in Management of Anemia Secondary to ChemotherapyPR Newswire(Mon, Jun 3)
- FDA raises drug safety concerns at Hospira facility in Indiaat Reuters(Thu, May 30)
- HOSPIRA INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Wed, May 29)
- Hedge Fund North Run Capital’s Top Q1 Stock Picksat Motley Fool(Tue, May 28)
- Back to Neutral on HospiraZacks(Tue, May 28)
- Wockhardt Drug Filings Seen Delayed After U.S. FDA Alertat Bloomberg(Fri, May 24)
- Moody's to review Hospira rating for downgradeAP(Wed, May 22)
- U.S. court ruling favors Cubist in patent case versus HospiraReuters(Mon, May 20)
- U.S. court ruling favors Cubist in patent case vs Hospiraat Reuters(Mon, May 20)
- Interesting HSP Put And Call For Julyat TheStreet(Mon, May 20)
- Cubist Pharmaceuticals shares leap late after ruling on patent casesat MarketWatch(Mon, May 20)
- Cubist move higher attributed to patent construction in suit against Hospiratheflyonthewall.com(Mon, May 20)
Key Statistics
| Forward P/E (1 yr): | 17.26 |
|---|
| P/S (ttm): | 1.50 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 2.03 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.51 |
|---|
| Mean Recommendation*: | 3.4 |
|---|
| PEG Ratio (5 yr expected): | 2.44 |
|---|
Business Summary
Hospira, Inc. provides injectable drugs and infusion technologies to develop, manufacture, distribute, and markets products worldwide. The company offers specialty injectable pharmaceuticals, which include approximately 200 injectable generic drug...
View More